PTC Therapeutics Finalizes Acquisition of Fabry Disease Gene Therapy

Key Facts

In a move that strengthens its rare disease portfolio, PTC Therapeutics has finalized the acquisition of the ST-920 gene therapy program for Fabry disease from Sangamo Therapeutics. This acquisition marks a strategic shift by adding a late-stage, one-time treatment asset to the company's pipeline. According to reports, the company now aims to complete its Biologics License Application (BLA) submission by the fourth quarter of 2026.

This expansion comes as biotech firms seek to bolster their pipelines with high-value genetic innovations. Based on the available data, the confirmation of the regulatory filing timeline provides investors with clearer visibility regarding the company's future growth trajectory. This step is part of a broader strategy to solidify PTC's position in the specialized gene therapy sector, leveraging newly acquired assets to expand its market reach.

Regarding market performance, PTCT stock stood at $65.37 at close on September 18, 2026, with a day high of $68.01 and a low of $65.18. Looking at the economic calendar, there are no upcoming domestic catalysts directly related to the biotech sector in the next few days, leaving the focus on the company's operational developments and progress toward its regulatory milestones.